Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes - Test2 - elhamkhani - TriplyDB

Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes

Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes

http://www.wikidata.org/entity/Q34223737

about

Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development Something old, something new and something very old: drugs for treating type 2 diabetes The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors Present status of clinical deployment of glucokinase activators A panel of diverse assays to interrogate the interaction between glucokinase and glucokinase regulatory protein, two vital proteins in human disease Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans Human genetics as a model for target validation: finding new therapies for diabetes.Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.A model-based approach to predict longitudinal HbA1c, using early phase glucose data from type 2 diabetes mellitus patients after anti-diabetic treatment.Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD.Many faces of monogenic diabetes Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient A phospho-BAD BH3 helix activates glucokinase by a mechanism distinct from that of allosteric activators Analysis of the co-operative interaction between the allosterically regulated proteins GK and GKRP using tryptophan fluorescence Enantioselective synthesis of tatanans A-C and reinvestigation of their glucokinase-activating properties.Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families.Discontinued in 2013: diabetic drugs.C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.Characterization of a novel glucokinase activator in rat and mouse models Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism.Repair of diverse diabetic defects of β-cells in man and mouse by pharmacological glucokinase activation Hepatic De Novo Lipogenesis in Obese Youth Is Modulated by a Common Variant in the GCKR Gene Phosphorus ingestion improves oral glucose tolerance of healthy male subjects: a crossover experiment TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models Familial adult onset hyperinsulinism due to an activating glucokinase mutation: implications for pharmacological glucokinase activation.Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour?Interactions between genetic background, insulin resistance and β-cell function.Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study.S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.Small-Molecule Allosteric Activation of Human Glucokinase in the Absence of Glucose.Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.Regulation of hepatic energy metabolism and gluconeogenesis by BAD Identification of mangiferin as a potential Glucokinase activator by structure-based virtual ligand screening.Compound 19e, a Novel Glucokinase Activator, Protects against Cytokine-Induced Beta-Cell Apoptosis in INS-1 Cells.Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus.Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes.Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.Glucokinase activators.

P2860

Q26830274-2BC17741-3D2F-452E-9E44-CAA1F40D3500 Q26865663-5EAA8B9C-88EF-4B2F-8D77-E5EB8FD513DA Q27333171-AF48F26F-68DD-4E22-B175-1C09B74239C1 Q27687521-6733A60C-E776-4CEC-B418-AF6D048DEFDD Q28080643-9B93D008-E0BE-4B28-810E-A214E4874418 Q28539913-43549CB8-32E3-4306-8B11-FE68C94DC261 Q28576077-26462466-02AB-4837-B75C-84B2B94E306F Q30234640-A98ECA29-CD6C-4E68-BAE2-680A2DDD47DC Q30597265-C7F4D246-7A1F-45A1-9D8F-736105917608 Q30619387-178AA4F2-9D5C-414F-8CA8-122EC1DCEF22 Q30713822-736D704F-85FB-4731-928E-8BA942868E94 Q33622236-ECBADF1B-4910-4F44-B601-889AABC92605 Q33759570-2E151DFD-FFB3-4702-B89F-526666372CB7 Q33855651-A74ADE96-4416-4A03-BB85-085E7B8B7EB2 Q33945387-1A6FA072-78F3-4BE3-9B4F-03E3140AD152 Q34019870-B77D6030-C2C1-44DA-A0F6-68439A08EB0D Q34211860-7D37BAF5-DC5B-4BD0-A2A5-880CD18E7714 Q34664870-5077FC60-182D-438D-AE4B-BF641B0D21DE Q34699045-9D7574B4-7155-4513-9AFF-93F7B5B80B5B Q35095351-E359A80D-CC80-4393-9541-0C40B93A5656 Q35578341-0BA71CC3-4ABF-4602-B568-2797D5565499 Q35611074-439E07E2-4C64-4C1F-BBEF-761516BD10CC Q35916492-459E313D-18A3-412F-AD7E-05FC1A66E139 Q36233027-5751432C-6C9E-400E-ADCA-4174E01B27D1 Q36282789-74CE4BF7-97C6-4023-9697-35B811BE891D Q36528937-75554FEF-49A7-43FF-AE40-6EF533DEF5BA Q36610334-417F28C9-4F5A-4E04-BE8C-DD9F895B6634 Q36790858-AE718C1E-5EF6-4B4D-B0AF-2924B148A9DF Q36908086-D430F06B-3A0F-45B5-AEC7-34BAB0C013E2 Q36965883-4D29D708-04CD-4FA7-BDED-0C5D11762B24 Q37342791-484AB022-2CD0-4F2B-82A4-6B0C868611CE Q37612020-FBDA90AB-11EE-4ADC-9385-4FB37416BBCD Q37665590-278E652D-9131-4D73-90EA-7841A28FA4C1 Q37677904-0C302084-7D67-41BB-82E3-14FB4AD3ED56 Q37710606-6FE61B00-08E6-405D-B7F1-04ED11359427 Q37725838-D22D6DFF-46A5-46F7-A95C-74FA3A350DA1 Q38069508-43969BC7-BBEC-4BAE-A230-B38269C069C9 Q38071706-A4132DE8-A405-432D-A1B6-D1359FFD92B9 Q38113101-E28B99A3-AEC1-4C83-A29C-D6FD560BCA6F Q38162928-460B8824-562B-4AD4-B004-E9503CC26CB4

P2860

Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes

http://www.wikidata.org/entity/Q34223737

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Effects of MK-0941, a novel gl ...... patients with type 2 diabetes

@ast

Effects of MK-0941, a novel gl ...... patients with type 2 diabetes

@en

Effects of MK-0941, a novel gl ...... patients with type 2 diabetes

@nl

type

label

Effects of MK-0941, a novel gl ...... patients with type 2 diabetes

@ast

Effects of MK-0941, a novel gl ...... patients with type 2 diabetes

@en

Effects of MK-0941, a novel gl ...... patients with type 2 diabetes

@nl

prefLabel

Effects of MK-0941, a novel gl ...... patients with type 2 diabetes

@ast

Effects of MK-0941, a novel gl ...... patients with type 2 diabetes

@en

Effects of MK-0941, a novel gl ...... patients with type 2 diabetes

@nl

P1433

Q34223737-2B85FA09-F3C6-4528-A796-6D94F53A8CEB

P1476

Q34223737-95EEFDD1-9901-4610-A632-782D35A9D97F

P2093

Q34223737-2CB743F1-FFDA-4267-9719-BB0C71C3EF02

Q34223737-3702D38D-6185-4B95-911C-6CAF8A9F0638

Q34223737-8ACEE6AB-510B-42D6-B0CE-719E3D392BEE

Q34223737-925D1E49-75DF-407B-A300-595B9E48DF31

Q34223737-A5B0D609-9926-4851-9AFC-CEE24C726C13

Q34223737-AD73107E-F943-4793-A78B-95129E643D6C

Q34223737-F0553B25-381F-41CD-A65E-C94CF4E4FB6F

Q34223737-F2D94360-8A31-4824-8F31-E34AAF3231CE

Q34223737-FFCF1F32-A2A0-4D37-9A8F-067F54C7F4B6

P2860

Q34223737-198EE7F0-3F39-4658-A6AE-D9690A064DAE

Q34223737-23B73636-F0E2-450E-AA0E-16626B070B19

Q34223737-35E8E61E-7B91-4953-B42B-220C090539AF

Q34223737-46CCC8E9-4AF1-4716-B958-C2FD280DC9DD

Q34223737-49BFB252-37BC-4884-940F-A62594E0492F

Q34223737-5CA1FF0B-D3DB-41FE-A421-7DC59099E40C

Q34223737-6995826C-06CC-4B06-B5A2-ADEA3666D77B

Q34223737-6F970C1F-AE69-443D-ABF1-ED1EE82F3CD5

Q34223737-86E48C9E-34D1-4D11-A887-730CEE9364A2

Q34223737-890AB2F1-7563-4D25-A331-27232B75702C

P304

Q34223737-F0204D06-A533-4F81-871D-2219E01698F2

P31

Q34223737-AC7726F6-5CCE-4B0F-848C-0DF314F39F98

P356

Q34223737-0A1945B4-2626-4293-8416-0EDA60D946E8

P407

Q34223737-FE733B87-E511-4D0D-8A94-6A8130972D25

P433

Q34223737-446C3726-D1CB-4E0B-AC3C-C54BDFEA3EC2

P478

Q34223737-7F2CC3C0-2736-4E10-B008-0AA363F07CE1

P577

Q34223737-2E25ABFE-BA84-48C0-A63D-3C049969396B

P5875

Q34223737-A67910CA-2E23-4996-86F0-05722542B0DB

P698

Q34223737-1FF78D00-06DA-43A3-ABB3-BA0F0B6A358A

P921

Q34223737-22262938-F8C0-4BAE-B017-FC983FA9AE0F

Q34223737-383E9EEC-8DD9-4620-9F45-957BB1CE7905

Q34223737-4F5B759C-39F2-45E0-AE5B-22B298E09E53

P932

Q34223737-B2B875D2-87F2-4E2C-A2EC-251D28CEDEA1

P356

P1433

P1476

Effects of MK-0941, a novel gl ...... patients with type 2 diabetes

@en

P2093

Barry J Goldstein

http://www.w3.org/2001/XMLSchema#string

Edmund Luo

http://www.w3.org/2001/XMLSchema#string

Gary E Meininger

http://www.w3.org/2001/XMLSchema#string

Himal Amin

http://www.w3.org/2001/XMLSchema#string

Keith D Kaufman

http://www.w3.org/2001/XMLSchema#string

Maria Alba

http://www.w3.org/2001/XMLSchema#string

Michael J Davies

http://www.w3.org/2001/XMLSchema#string

Russell Scott

http://www.w3.org/2001/XMLSchema#string

Yue Shentu

http://www.w3.org/2001/XMLSchema#string

P2860

Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations

Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels

Longitudinal data analysis for discrete and continuous outcomes

Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study.

The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group.

The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes.

The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population.

Assessing the potential of glucokinase activators in diabetes therapy.

The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy.

Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia.

P304

2560-2566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC11-1200

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51714550

http://www.w3.org/2001/XMLSchema#string

P698

21994424

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3220852

http://www.w3.org/2001/XMLSchema#string